

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Solid tumors	Tumor necrosis factor- α (TNF- α)	<p>Mouse studies suggest low-dose, recombinant TNF-α could be useful as an adjuvant for cancer immunotherapy. In mice with pancreatic neuroendocrine tumors, Tnf-α modified to target tumor vasculature increased survival compared with control. In the mice, low-dose, recombinant Tnf-α plus a cancer vaccine increased survival compared with either component alone. Next steps include testing recombinant TNF-α in combination with approved cancer vaccines.</p> <p><i>SciBX</i> 5(19); doi:10.1038/scibx.2012.492 Published online May 10, 2012</p>	Use of TNF- α in combination with chemotherapy has been patented; unavailable for licensing	<p>Johansson, A. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online April 30, 2012; doi:10.1073/pnas.1118296109 Contact: Ruth Ganss, The University of Western Australia, Perth, Western Australia, Australia e-mail: ganss@waimr.uwa.edu.au</p>